Drug intelligence / Profile preview

GLS-7100

Development stage: Preclinical
Lead developer: GeneOne Life Science
Modality: Recombinant Proteins and Enzymes, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies

Overview

GLS-7100 is a DNA-based recombinant factor VIII therapeutic developed by GeneOne Life Science, Inc. for the treatment of Hemophilia A. This innovative approach aims to enable patients with Hemophilia A to produce functional coagulation factor VIII within their own cells, thereby restoring the blood clotting cascade. It is expected to offer an effective and cost-efficient alternative to existing therapies for this X-linked bleeding disorder, which results from mutations in the gene encoding for coagulation factor VIII.

Targets

F8 (Coagulation Factor VIIIa)

Beyond the preview

Go deeper on GLS-7100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLS-7100.

Explore the full profile